Keyword: Apollo Endosurgery
The FDA updated its warning on liquid-filled intragastric balloons used to treat obesity.
Apollo Endosurgery picked up a CE mark for its weight-loss balloon, which is designed to remain in the stomach for 12 months.
The FDA updated its warning on liquid-filled intragastric balloons used to treat obesity after receiving five new reports of patient deaths.
Allurion Technologies has raised $27 million in series C funding for its swallowable, procedureless, weight-loss balloon.
The FDA has issued a warning about two devices used to treat obesity after receiving upward of 40 reports of adverse events.
Apollo Endosurgery has struck a deal to acquire monoclonal antibody-focused Lpath in a reverse merger that will see Apollo's investors pouring about $29 million into the combined company.